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A B S T R A C T
Cardiac ﬁbrosis is a hallmark of heart failure for which there is no eﬀective pharmacological therapy. By genetic modiﬁcation and in vivo inhibitor approaches it was
suggested that the Rho-associated kinases (ROCK1 and ROCK2) are involved in pro-ﬁbrotic signalling in cardiac ﬁbroblasts and that they may serve as targets for
anti-ﬁbrotic therapies. We demonstrate that simultaneous inhibition of ROCK1 and ROCK2 strongly interfered with tissue formation and their biomechanical
properties in a model of engineered connective tissue (ECT), comprised of cardiac ﬁbroblasts and collagen. These eﬀects were observed with both rat and human ECT.
Inhibitors of diﬀerent chemistries, including the isoquinoline inhibitors Fasudil and H1152P as well as the pyrazol-phenyl inhibitor SR-3677, showed comparable
eﬀects. By combined treatment of ECT with TGF-β and H1152P, we could identify ROCK as a mediator of TGF-β-dependent tissue stiﬀening. Moreover, expression
analyses suggested that lysyl oxidase (LOX) is a downstream target of the ROCK-actin-MRTF/SRF pathway and inhibition of this pathway by Latrunculin A and CCG-
203971 showed similar anti-ﬁbrotic eﬀects in the ECT model as ROCK inhibitors. In line with the collagen crosslinking function of LOX, its inhibition by β-
aminopropionitrile resulted in reduced ECT stiﬀness, but let tissue compaction unaﬀected. Finally, we show that ROCK inhibition also reduced the compaction and
stiﬀness of engineered heart muscle tissues. Our results indicate that pharmacological inhibition of ROCK has a strong anti-ﬁbrotic potential which is in part due to a
decrease in the expression of the collagen crosslinking enzyme lysyl oxidase.
1. Introduction
Cardiac ﬁbrosis is a self-perpetuating process, which takes place in
the diseased heart. The increase in interstitial and perivascular extra-
cellular matrix accumulation leads to diastolic dysfunction, diﬀusion
problems, cardiomyocyte death and arrhythmias. Therapeutically,
blockade of the renin-angiotensin II (Ang II)-aldosterone system by
angiotensin converting enzyme (ACE) inhibitors or angiotensin II-type1
receptor antagonists can slow down ﬁbrosis [1], but it is not yet pos-
sible to halt or reverse ﬁbrosis. Cardiac ﬁbrosis is driven by myoﬁ-
broblasts, which arise mainly from transdiﬀerentiation of resident
cardiac ﬁbroblasts after exposure to mediators like Ang II and trans-
forming growth factor-β as well as in response to altered biomechanical
properties of their surroundings [2–5]. Understanding the molecular
events underlying ﬁbrosis is essential to identify new therapeutic anti-
ﬁbrotic strategies for the treatment of heart failure.
The RhoA-associated kinases ROCK1 and ROCK2 are serine/threo-
nine kinases belonging to the family of AGC-kinases. Both have been
suggested to play a role in cardiac disease and in remodelling of the
myocardium [6]. Studies using ROCK1 and ROCK2-deﬁcient mice
indicate that ROCKs regulate cardiomyocyte apoptosis and cardiac ﬁ-
brosis [7–12]. In addition, ROCK2 was shown to contribute to cardiac
hypertrophy [8,11]. In vitro, ROCKs regulate ﬁbrosis-associated genes,
including connective tissue growth factor (CTGF), ﬁbroblast growth
factor 2 (FGF2), α-smooth muscle actin (SMA) and pro-collagen I
[10,13–15]. ROCKs are also implicated in cardiac ﬁbroblast migration
and proliferation [16–18]. All in vitro studies have been carried out
using puriﬁed cardiac ﬁbroblasts in 2D cultures, and the eﬀects of
ROCK inhibition on the behaviour of cardiac ﬁbroblasts embedded in a
more physiological 3D environment have not been investigated.
Tissue engineering approaches are improving our understanding of
cellular processes taking place in a 3D environment, as well as facil-
itating the discovery of druggable targets using drug screening. The
idea of using engineered connective tissues to study ﬁbrotic processes
was brought up in the late 80s of the last century [19]. In the following
these tissues were mainly used to understand the biology of embedded
ﬁbroblasts and to learn more about their inﬂuence on biomechanical
tissue properties [20]. A further development of these tissues led to the
nowadays widely used heterogeneous cardiac tissues consisting of
matrix factors, cardiomyocytes and non-cardiomyocytes [21–23].
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Unfortunately, homogeneous cardiac ﬁbroblast tissues has received less
attention, although they could serve as simple test beds to speciﬁcally
address cardiac ﬁbrosis mechanisms. We introduced a ring-shaped en-
gineered connective tissue (ECT) model composed of cardiac ﬁbroblasts
and collagen I, which oﬀers several advantages compared to other
models like ﬂoating discs, aggregates with or without collagen, and
sheet-like tissues [24–28]. In the ring-shaped model, the cells compress
the matrix against a central stiﬀ rod, which does not allow them to
contract the tissue into an undeﬁned ball-like structure. This enables
the simple quantiﬁcation of tissue compaction by measuring the cross
sectional area of the tissues. Moreover, the stiﬀ rod applies a moderate
tension to the cells, which can induce the alignment of ﬁbroblasts along
the tension axis mimicking the natural situation [29]. The ring-shape
minimizes in addition non-uniformity in tissue geometry and environ-
mental diﬀerences aﬀecting the embedded cells [29]. And most im-
portantly, the ring-shape enabled us to measure the biomechanical
properties with hooks and a rheometer without damaging the tissue by
clamps or similar. We perform linear ultimate destructive tensile
measurements in order to obtain information on tissue stiﬀness
(Young's modulus, slope of the elastic region of the stress-strain curve)
and on the strain to failure point reﬂecting the maximal extensibility of
the tissue. We have previously demonstrated that this model is suitable
to perform gain and loss of function experiments as well as small mo-
lecule studies [15,18,30].
Here, we introduce a two-tiered approach to identify anti-ﬁbrotic
targets in a homogeneous rat and human cardiac ﬁbroblast- (rECT and
hECT) and heterogeneous rat cardiac cell- (rEHM) speciﬁc context. Both
models allow for direct and quantitative assessments of ﬁbroblasts on
viscoelastic properties and in case of rEHM an association to contractile
function. By making use of 2D, rECT, hECT and rEHM models we
identiﬁed that ROCK inhibition results in a substantial loss of tissue
compaction and a decline in tissue stiﬀness. We further observed that
ROCK inhibition blunts the TGF-β-dependent increase of tissue stiﬀness
and that tissue stiﬀening involves a ROCK-mediated regulation of the
collagen cross-linking enzyme lysyl oxidase (LOX).
2. Material and methods
2.1. Material
All cell culture reagents for the growth of rat cardiac cells were
purchased from Invitrogen, unless otherwise stated. Cell culture plastic
was obtained from Greiner, Sarstedt or Nunc. All ﬁne chemicals were of
highest quality available and were purchased from Sigma Aldrich
(DAPI, FITC-phalloidin, Hoechst 33342, β-aminopropionitrile, CCG-
203971), Biomol (Fasudil, H1152P, SR-3677), Preprotech (TGF-β),
Enzo Life Sciences (Latrunculin A) or Merck (MMP 408). Antibodies
were purchased from BD Biosciences (ROCK1, 611,136), Santa Cruz
(ROCK2, sc-5561), Origene (LOX, TA337077), Zytomed Systems
(GAPDH, RGM2-6C5) and Sigma Aldrich (α-tubulin, T 5168; β-actin, A
2228; α-smooth muscle Actin (SMA), A 5228). All primers were syn-
thesized by Euroﬁns Genomics.
2.2. Animal care and housing
Animals were used in accordance with the guidelines (§4 Absatz 3
Deutsches Tierschutzgesetz) of the institutional animal care and use
committee Niedersächsisches Landesamtes für Verbraucherschutz und
Lebensmittelsicherheit (LAVES, Germany). Rats were kept on a 12 h
light/dark cycle with water and food ad libitum.
2.3. Isolation of neonatal rat cardiac cells
Neonatal rat cardiac ﬁbroblasts (NRCF) and cardiomyocytes
(NRCM) were isolated using the neonatal heart dissociation kit, mouse
and rat from Miltenyi Biotec. Forty to sixty neonatal Wistar rats (P0-P3)
were decapitated, a thoracotomy performed, and the heart including
the vascular pedicle was excised. The atria, vascular pedicle and re-
maining connective tissue were dissected. The tissue was digested ac-
cording to the manufacturer's instructions and dispersed with the
gentleMACS dissociator (Miltenyi Biotec) using the gentleMACS pro-
gram htumor3.01. Cells were then resuspended in NCM medium
(DMEM GlutaMAX 1 g/L glucose, 10% fetal calf serum (v/v) 1% peni-
cillin-streptomycin (v/v)) and strained through a 250 μm pore stainless
steel mesh. The cell suspension was centrifuged, the supernatant was
discarded, and the pellet resuspended in NCM medium. This cell mix-
ture was either directly used to prepare engineered heart muscle tissues
(EHM) or further processed to purify the fraction of cardiac ﬁbroblasts.
To obtain ﬁbroblasts, 8× 106 cardiac cells were seeded on a 15 cm cell
culture dish in NCM medium and incubated for 45min in a humidiﬁed
incubator (37 °C, 5% CO2). The unattached cardiomyocytes were re-
moved with several washing steps. The attached NRCF were cultivated
in NRCF growth medium (DMEM GlutaMAX 4.5 g/L glucose, 10% fetal
calf serum (v/v), 1% penicillin-streptomycin (v/v) 1% non-essential
amino acids (v/v)). For experiments NRCF from passage 2 to 3 were
used.
2.4. Cultivation of normal human ventricular cardiac ﬁbroblasts
Normal human ventricular cardiac ﬁbroblasts (hCF) were purchased
from Lonza. The cells had been isolated from a male Caucasian donor.
They were cultivated in FGM-3 growth medium (Lonza) according to
the manufacturer's recommendations. For the preparation of hECT, cell
passages 3 to 4 were used.
2.5. Inhibitor treatments
Dilution of H1152P was carried out in DMSO. We therefore added
DMSO in an equal volume to all conditions including the controls to
avoid DMSO eﬀects.
2.6. Proliferation assay
The proliferation of NRCF was analysed over six days. In a 24-well
plate 104 NRCF were seeded per well in NRCF growth medium and
treated with 300 nM or 3 μM H1152P every day starting 24 h after
seeding. The cells were ﬁxed with 4% paraformaldehyde (PFA) in PBS
for 15min 24 h after seeding and 1, 2, and 6 days later. The cell nuclei
were stained with 10 μg/mL Hoechst 33342 in PBS for 30min.
Automated evaluation of cell number was performed using the
Cellavista system (Synentec).
2.7. Adhesion assay
NRCF were treated for 24 h with 300 nM or 3 μM H1152P, or left
untreated. The cells were then replated in NRCF growth medium con-
taining the ROCK inhibitors on uncoated or collagen type I-coated
(50 μg/cm2) 12-well plates. After 20, 40 and 60min ten bright-ﬁeld
images per condition were acquired using the time-lapse function of an
inverted microscope (Olympus) equipped with a XM10 camera
(Olympus), 10× objective and a humidiﬁed climate chamber set to
37 °C, 5% CO2. The number of adhered cell and all cells were manually
counted.
2.8. Apoptosis assay
NRCF were pre-conditioned for 24 h with reduced serum (2%)-
containing NRCF medium and treated with 300 nM or 3 μM H1152P for
48 h. As a positive control, cells were treated with 3 μM staurosporine
for 3 h. Upon treatment, cells were washed twice with PBS and stained
with FITC-conjugated annexin-V and propidium iodide (PI) according
to the manufacturer's instructions (Annexin-V-FLUOS Staining Kit,
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Roche). The stained cells were imaged under an Olympus IX81 inverted
ﬂuorescence microscope.
2.9. Analysis of the actin cytoskeleton, bi-nucleation and cell area of NRCF
in 2D cultures
NRCF were cultured in NRCF growth medium in the presence of
300 nM or 3 μMH1152P. After 48 h the cells were washed with PBS and
ﬁxed with 4% paraformaldehyde in PBS for 15min. After three PBS
washing steps permeabilization was carried out in 0.02% Triton X-100
in PBS for 3min. Staining of the actin cytoskeleton with 0.5 μg/mL
FRITC-labelled phalloidin and of the nuclei with 1 μg/mL DAPI in PBS
was performed for 1 h at room temperature in the dark. Finally, the
cells were washed twice with PBS and imaged using an inverted
ﬂuorescence microscope (Olympus) with a XM10 camera (Olympus)
and a 10× objective. Bi-nucleated cells were counted and cell size
analysis was performed with the free hand tool of ImageJ.
2.10. Preparation and cultivation of rat engineered connective tissues
(rECT)
To generate rECT, 1.2 mg rat tail collagen type I (puriﬁed in-house
or obtained from Corning) was neutralized with 0.1 N NaOH, buﬀered
with 2× DMEM (20% 10× DMEM (v/v), 20% horse serum (v/v) 2%
penicillin-streptomycin (v/v)) and then mixed with 1.7×106 NRCF per
tissue. The mixture was cast into custom-made circular moulds (dia-
meter of the inner spacer 8mm) and allowed to gel for 1 h in a humi-
diﬁed incubator at 37 °C and 5% CO2. After condensation, NRCF growth
medium was added to the casting mould and the tissues were cultured
for 5 days without further treatment or as indicated in the presence of
10 μM Fasudil, 3 μM H1152P, 3–170 nM SR-3677, 100 μM β-amino-
propionitrile (BAPN), 5 ng/mL TGF-β1, 7 ng/mL LatA, 50 μM CCG-
203971 and/or 10 μM MMP408. The reagent-containing as well as the
control media were changed every day. rECT from diﬀerent experi-
ment.
2.11. Preparation and cultivation of human engineered connective tissues
(hECT)
To generate hECT, 0.6 mg bovine collagen type I (Collagen solutions
LLC) was neutralized with 0.1 N NaOH, buﬀered with 2× DMEM and
then mixed with 0.75×106 hCF per tissue. The mixture was cast into
custom-made circular moulds and allowed to gel for 1 h in a humidiﬁed
incubator at 37 °C and 5% CO2. The used moulds were half the size
(diameter of the inner spacer 4mm) of those used for rECT preparation.
After condensation, FGM-3 growth medium was added to the casting
mould and the tissues were cultured for 5 days without further treat-
ment or as indicated in the presence of 10 μM Fasudil or 3 μM H1152P.
The inhibitor-containing medium was changed every day.
2.12. Preparation and cultivation of rat engineered heart muscle tissues
(rEHM)
EHM were generated as described before [31]. In brief, 0.8 mg rat
tail collagen type I (puriﬁed in-house) was neutralized with 0.1 N
NaOH, buﬀered with 2× DMEM and mixed with 10% Matrigel
(Corning) and 2.5× 106 isolated rat cardiac cells per tissue. The rEHMs
were cast into custom-made circular moulds (diameter of the inner
spacer 8mm) and allowed to solidify for 1 h in a humidiﬁed incubator
at 37 °C and 5% CO2. After gelation, rEHM culture medium (DMEM
GlutaMAX, 1 g/L glucose, 10% horse serum (v/v), 1% penicillin-strep-
tomycin (v/v)) was added to the casting mould. The medium was
changed the next day and then every second day thereafter. On culture
day eight, the rEHMs were subjected to dynamic mechanical stretch at
1 Hz for 24 h, then at 2 Hz for another six days. During this phase, the
rEHMs were treated with 10 μM Fasudil or 3 μM H1152P. The medium
was changed every other day.
2.13. Cross-sectional area analysis of engineered tissues
The engineered tissues were taken out of their casting moulds (ECT)
or were removed from the phasic stretchers (rEHM), transferred in a
multi-well plate and imaged with a stereomicroscope (Stereo
Lumar.V12, Zeiss). Images of the tissues were taken from top and from
the side. Horizontal line scan analysis was performed at a minimum of 3
positions per tissue arm per image. The cross-sectional area (CSA) was
calculated based on the means of the line lengths, which approximately
reﬂect the tissues' diameters (mean diameter top dt, mean diameter side
ds), with the help of the elliptic area equation CSA=dt/2 x ds/2 x π.
We used the CSA in the following as a measure for diﬀerences in tissue
compaction, which describes changes that occur during the gelation of
collagen, the cell-driven compression of the matrix and/or the re-
modelling of the matrix by secreted factors.
2.14. Destructive tensile strength of engineered tissues
Destructive tensile strength of engineered tissues was performed
using an RSA-G2 rheometer (TA Instruments) to assess their viscoelastic
properties. The engineered tissues were transferred into an organ bath
containing PBS at 37 °C and ﬁxed between two custom-made hooks.
Tissues were then stretched at a constant linear rate of 0.05mm/s for
rat and 0.03mm/s for human tissues until the point of rupture.
2.15. Stress-strain analysis of destructive tensile strength measurements
To calculate the given parameters (Young's modulus, strain to
failure point) from the destructive tensile strength measurements, the
measured force values (mN) were divided by the determined CSA
(mm2) to obtain stress values (kPa) and these were plotted against the
gap in mm (distance between the upper and lower hook) in GraphPad
Prism. The obtained curves typically displayed the following regions:
An initial region in which only background stress was measured, a short
toe region, an elastic region in which the stress versus gap values were
linear, a ﬂattened plastic region, and ﬁnally a region of failure which
was characterized by a sudden drop in stress due to the rupture of the
tissues. To calculate the strain values, the beginning of the toe region
was identiﬁed and the corresponding gap length was considered as L0.
The strain equation (Ltotal-L0)/L0 was used to transform the gap values,
and the stress values at the beginning of the toe region were used for
background subtraction. The slope of the elastic region was determined
by linear regression and is presented in this work as Young's modulus.
The strain to failure point, characterized by the sudden drop in stress,
was identiﬁed manually. Due to the material-dependent variations in
the absolute values, we compared only conditions which had been
tested in parallel.
2.16. Isometric force measurements of rEHM
After 14 days in culture, the rEHM functionality was assessed by
isometric force measurements in an organ bath containing oxygenated
Tyrode's solution at 37 °C. Prior to force measurements, the force
transducers were calibrated. The rEHM were stretched by stepwise
length adjustment (in 125 μm steps) at 2 Hz electrical ﬁeld stimulation
in the presence of 1mM extracellular calcium until the length of max-
imum force generation was reached. The contractile forces of rEHM
were measured in the presence of increasing extracellular calcium
(0.2–2.4mM).
2.17. Re-isolation of cells from rECT
rECT were dissociated by incubation in 2mg/mL collagenase I in
calcium-containing PBS in the presence of 20% FCS for 2 h at 37 °C. The
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Fig. 1. ROCK inhibition reduced compaction and stiﬀness of rECT. rECT were generated with NRCF and collagen I and were cultured for 5 days in the absence
(Control) or presence of 10 μM Fasudil or 3 μM H1152P. A) Representative images of rECT are shown. B) The cross sectional areas (CSA) were determined by image
analysis. Given are the means+SEM of 13 to 15 individual tissues from 3 independent experiments. Diﬀerences were analysed by 1way-ANOVA, *p < .05 vs.
Control. C) Representative stress-strain curves from destructive tensile measurements are shown. D) The Young's moduli were calculated based on the obtained stress-
strain curves. Given are the means+SEM of 9–13 rECT from 3 independent experiments. Diﬀerences were evaluated by 1way-ANOVA, *p < .05 vs. Control. E) The
strain to failure point was extracted from the obtained rheology data. Given are the means+SEM of 13–17 rECT from 3 independent experiments. F–H) The cells were
re-isolated from the rECT and the total cell numbers (F), cell viabilities (G) and cell volumes (H) were analysed. Given are the means+SEM of 6 to 8 rECT from 3
independent experiments. I, J) The re-isolated cells were ﬁxed and FACS analysis was performed. The percentages of bi-nucleated cells (I) and of cells in diﬀerent cell
cycle phases (J) were determined. Shown are the means+SEM of 4 to 6 isolations. Diﬀerences in the cell cycle stage were evaluated by 2-way-ANOVA, *p < .05 vs.
Control.
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tissues were then washed with PBS and further incubated in Accutase
(Millipore), 0.0125% Trypsin, and 20 μg/mL DNAse (Calbiochem) for
30min at 37 °C. The cells were mechanically separated and the enzy-
matic activity was stopped by transferring them into PBS containing 5%
FBS. After centrifugation for 10min at 100 g and 4 °C, cells were re-
suspended in PBS containing 5% FBS and counted with a CASY TT
system (Roche).
2.18. FACS analysis
For FACS analysis cells isolated from rECT or cultured in 2D after
detachment were used. The cells were ﬁxed in ice-cold 75% ethanol for
at least 30 min at 4 °C and then washed twice in PBS. For propidium
iodide staining, the cells were subsequently treated with 100 μg/mL
RNase. To stain the DNA, cells were then incubated either with 50 μg/
mL propidium iodide for 30min at 37 °C or with 10 μg/mL Hoechst
33342 for 30min at 4 °C, centrifuged for 5min at 300 g and 4 °C, re-
suspended in PBS and then analysed by ﬂow cytometry. Appropriate
regions and gates strategy to quantify the results were hierarchically
deﬁned as follows: (1) gating of cells based on forward scatter area
(FSC-A) and sideward scatter area (SSC-A) also allowing the exclusion
of cell debris, (2) gating of single cells based on DNA signal width
versus FSC-A, (3) gating of cell cycle phases based on DNA signal area
versus FSC-A. Cells were run on a LSRII SORP Cytometer (BD
Biosciences) and analysed using Flowing software. At least 10,000
events were analysed per sample.
2.19. Immunoblot analysis
Proteins were isolated from treated 2D and 3D cultures with
Cytobuster (Novagen), centrifuged and the supernatant supplemented
with 4× Laemmli buﬀer. The cell lysates were denatured and subjected
to SDS-PAGE followed by transfer onto a nitrocellulose membrane.
Membranes were blocked with 1× Rotiblock (Carl Roth) for 1 h at
room temperature, washed once with TBST (10mM Tris pH 7.4,
150mM NaCl, 0.1% Tween 20) and incubated overnight with the re-
spective antibodies. After three washing steps with TBST, the mem-
branes were incubated with the secondary antibodies (anti-mouse
Sigma-Aldrich A9044, anti-rabbit Sigma-Aldrich A9169) for 1 h. After
three ﬁnal washing steps, the secondary antibodies were detected with
SuperSignal West Femto Maximum Sensitivity Substrate (Thermo
Scientiﬁc) using a ChemiDoc imaging system (Biorad).
2.20. qPCR analysis
RNA was isolated from ECT using a phenol-chloroform method.
TriFast (1 mL, Peqlab) was added per tissue and incubated at 4 °C
overnight to dissolve the collagen hydrogel. The following day, re-
maining pieces of tissue were mechanically dissociated by vigorous
pipetting and subsequent RNA isolation was performed according to the
manufacturer's protocol. To further clean up the RNA, the clean-up
protocol of the RNeasy Mini Kit (Qiagen) was used. For isolation of RNA
from 2D NRCF cultures, QIAshredder spin columns and the RNeasy
Mini Kit (Qiagen) were used according to manufacturer's protocols. The
isolated total RNA was subjected to cDNA synthesis with the help of the
RevertAid ﬁrst strand cDNA synthesis kit (Fermentas). Quantitative
real-time PCR was performed with 5× HOT FIREPol EvaGreen qPCR
Mix Plus (Solis Biodyne) in 384-well plates (Applied Biosystems) with a
ViiA 7 real-time PCR system (Applied Biosystems). Primers used for
ampliﬁcation are given in the supplement. All values were normalized
to a combination of the housekeeping genes porphobilinogen deami-
nase (PBGD) and β-glucuronidase (GUSB), or PBGD and hypoxanthine
phosphoribosyltransferase 1 (HPRT) and calculated either by a stan-
dard curve or by the ΔΔCT equation.
3. Results
3.1. ROCK inhibition reduces compaction and stiﬀness of rECT
The ﬁrst aim of our study was to test the inﬂuence of diﬀerent pan-
ROCK inhibitors on the behaviour of cardiac ﬁbroblasts in a 3D en-
vironment. We decided to compare at ﬁrst the clinically approved
ROCK inhibitor Fasudil with its more potent and speciﬁc homolog
H1152P [32]. We generated rECT composed of neonatal rat cardiac
ﬁbroblasts (NRCF) and rat tail collagen I and treated the tissues with
Fasudil (10 μM) or H1152P (3 μM). After 5 days in culture the dimen-
sions of rECT were analysed. Compared to untreated controls, the cross-
sectional areas of the Fasudil- and H1152P-treated rECT were sig-
niﬁcantly increased and the tissues appeared to be less compact, which
argues for changes in cell-driven compression of the matrix and/or its
remodelling by secreted factors. (Fig. 1A, B). Next, the tissues were
subjected to rheometry to assess their biomechanical properties. Re-
presentative stress-strain curves are shown in Fig. 1C. Based on these
curves the Young's moduli were calculated showing that Fasudil and
H1152P strongly reduced tissue stiﬀness (Fig. 1D). No change in tissue
extensibility (strain to failure point) was detected (Fig. 1E). To exclude
cell loss as a cause for the observed changes, we re-isolated the cells
from the tissues. The cell yield was comparable in all groups, as well as
the cell viability (Fig. 1F, G). We could further exclude a change in cell
size as an explanation for our ﬁndings (Fig. 1H). By FACS analysis of re-
isolated and ﬁxed cells we found no change in the percentage of bi-
nucleated cells in the H1152P-treated rECT (Fig. 1I) and a moderate
increased number of cells in G2M phase (Fig. 1J). These results de-
monstrate that ROCK inhibition with Fasudil or H1152P strongly in-
terferes with the ability of cardiac ﬁbroblasts to form compact and stiﬀ
tissues. In line with their described pharmacological proﬁles, the more
potent and selective inhibitor H1152P elicited more prominent eﬀects
[33]. As Fasudil and H1152P share the same isoquinoline chemistry, we
further carried out a concentration-response analysis for the largely
uncharacterized compound SR-3677. SR-3677 possesses a pyrazol-
phenyl scaﬀold and was described to more potently inhibit ROCK2 than
ROCK1 as well as to inhibit eﬀectively in the nanomolar range [34]. We
found that at the highest concentration of 170 nM, which exceeds 3-fold
the IC50 of ROCK1 and 50-fold the IC50 of ROCK2, SR-3677 showed a
similar reduction in rECT compaction and in the calculated Young's
modulus as H1152P (Suppl.-Fig. 1). These data together strongly sup-
port a role of ROCKs in rECT tissue compaction and stiﬀening and de-
monstrates that the rECT model is suitable for drug screening and
comparison.
3.2. ECT compaction and stiﬀness are diﬀerentially regulated by TGF-β and
ROCK
ROCK signalling had been described to be part of the non-canonical
TGF-β signal pathway in cardiac ﬁbroblasts [10]. We therefore used our
rECT model to analyse the impact of ROCK inhibition on TGF-β-induced
changes in rECT properties. Treatment of rECT with TGF-β did not alter
tissue compaction (Fig. 2A, B), but increased tissue stiﬀness sig-
niﬁcantly (Fig. 2C, D). As shown in Fig. 1, ROCK inhibition with 3 μM
H1152P impaired both processes. Treatment with TGF-β prevented the
reduction in tissue compaction and tissue stiﬀness induced by H1152P
(Fig. 2A–D). These results indicate that TGF-β signalling compensates
for the eﬀect of ROCK inhibition on tissue compaction, and that ROCK
inhibition reduces the pro-ﬁbrotic eﬀect of TGF-β as demonstrated by
the reduction in tissue stiﬀness.
3.3. ROCK inhibition reduces the transcription of secreted proteins in rECT
One possible explanation for the role of ROCKs in rECT tissue
properties is that they regulate the composition of the extracellular
matrix. We therefore investigated the expression of a panel of genes
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involved in forming, modifying or regulating the extracellular matrix,
focusing particularly on those linked to collagens, since this was used to
embed the cardiac ﬁbroblasts in rECT. We extracted RNA from rECT
treated with and without the ROCK inhibitors Fasudil and H1152P and
performed qPCR analysis. In contrast to previous reports [10,13], we
did not detect any ROCK-mediated diﬀerences in the expression of the
dominant cardiac collagen isoforms collagen 1a1 (col1a1) and also not
of collagen 3a1 (col3a1). Similarly, there were no diﬀerences in the
expression of the collagen organizers biglycan and decorin, the ﬁbrosis
markers CTGF and galectin-3 (LGALS3) or the major pro-ﬁbrotic cyto-
kine TGF-β. In contrast, the transcription of the collagen crosslinker
lysyl oxidase (LOX) and the ﬁbrosis inducer hyaluronan synthase 2
(HAS2) and were decreased by Fasudil and H1152P treatment. H1152P
also inhibited the transcription of the elastase MMP12 signiﬁcantly.
Conversely, MMP2 and ROCK2 increased following H1152P treatment
(Fig. 3A). We next validated the expression changes which were con-
sistent between Fasudil and H1152P on protein level. We performed
immunoblot analyses of LOX and for control of ROCK1 and ROCK2 after
1 day and 5 days of treatment. LOX expression was reduced in ECT
treated for 1 day with Fasudil and H1152P. After 5 days treatment the
changes were not as prominent as after 1 day (Fig. 3B). ROCK1 was
signiﬁcantly increased by H1152P after 1 day (Fig. 3C), ROCK2 showed
no signiﬁcant changes in its protein levels at any condition (Fig. 3D).
We further tried to detect HAS2, however, due to the high albumin
content in our tissues we were not able to identify a reliable signal (data
not shown).
3.4. ROCKs alter cardiac ﬁbroblast cell shape, cell cycle progression and
LOX expression in 2D cultures
To analyse how ROCK inhibitors aﬀect cardiac ﬁbroblast function,
we treated NRCFs with 300 nM and 3 μM H1152P for 48 h in 2D culture
conditions. H1152P appear to reduce the complexity of the intracellular
actin network (Fig. 4A). The cell area was increase by H1152P, which
was not based on a general increase in cell size (Fig. 4B, C). We then
investigated the ability of the cells to adhere to plastic or collagen-
coated surfaces as a possible explanation for the compaction defect
observed in ROCK inhibitor-treated rECT, but no diﬀerence between
control and H1152P-treated NRCFs was observed. As expected the ad-
hesion to collagen-coated surfaces was in general faster than to un-
coated plastic (Fig. 4D). Based on our observed cell cycle changes in-
duced by ROCK inhibitors in rECT, we studied cell proliferation by
automated counting of cell nuclei, determined the number of bi-nu-
cleated cells and performed cell cycle analysis by FACS. Three μM
H1152P but not 300 nM fully blocked proliferation and increased the
number of bi-nucleated as well as of G2M-arrested cells by around 3-
fold (Fig. 4E-G). This was accompanied by an increase in apoptosis
(Fig. 4H), which might be due to inhibition of cytokinesis. We next
Fig. 2. rECT compaction and stiﬀness are diﬀerentially regulated by TGF-β and ROCK. rECT were generated with NRCF and collagen I and were cultured for 5 days in
the absence (Control) or presence of 3 μM H1152P and/or 5 ng/mL TGF-β1. A) Representative images of rECT are shown. B) The cross sectional areas (CSA) were
determined by image analysis. Given are the means+SEM of 3 independent experiments. Diﬀerences were analysed by 1way-ANOVA, *p < .05 vs. Control. C)
Representative stress-strain curves from destructive tensile measurements are shown. D) The Young's moduli were calculated based on the obtained stress-strain
curves. Given are the means+SEM of 3 independent experiments. Diﬀerences were evaluated by 1-way-ANOVA, *p < .05 vs. Control.
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determined the eﬀect of H1152P on gene expression in 2D cultures after
48 h and 5 days of treatment (Fig. 5). LOX RNA levels were con-
centration-dependently decreased in H1152P-treated cells after 48 h
and 5 days (Fig. 5A). The respective protein levels showed similar
changes, however being only signiﬁcant after 48 h. LOX expression was
lower after 5 days compared to 48 h in controls and in the presence of
300 nM H1152P (Fig. 5F, G). To validate the inhibition of ROCK, we
further investigated the expression of α-smooth muscle-actin (SMA), a
known target of the RhoA/ROCK pathway [35]. Comparable to LOX,
SMA was reduced on RNA level at both time points (Fig. 5B) as well as
in rECT after 5 days (Fig. 5C). SMA protein was also signiﬁcantly re-
duced after 48 h. In contrast to LOX, SMA expression tends to increase
over the 5 days culture period (Fig. 5F, H). ROCK1 and ROCK2 RNA
levels showed at 3 μM H1152P an inverse regulation at the two dif-
ferent time points (Fig. 5D, E). On protein level only the moderate in-
crease after 48 h was consistent with the RNA data (Fig. 5F, I, J). We
further investigated potential changes in the RNA levels of Col1a1,
Col3a1, HAS2, MMP2 and MMP12 after 48 h and 5 days of treatment.
(Suppl.-Fig. 2). Similar to the rECT model, both collagens were not
regulated (Suppl.-Fig. 2A, 2B) and after 5 days of treatment HAS2 was
decreased and MMP2 increased (Suppl.-Fig. 2C, 2D). MMP12 showed in
2D culture an opposite regulation compared to rECT (Suppl.-Fig. 2E).
3.5. Inhibition of actin polymerization and MRTF translocation reduced
rECT compaction and stiﬀness as well as LOX expression
The expression of LOX was suggested to be regulated by the actin-
dependent MRTF/SRF activation, which is a known RhoA/ROCK
pathway [35,36]. We therefore tested next the impact of the actin
polymerization inhibitor LatA and the MRTF translocation inhibitor
CCG-203971 on rECT properties and on the expression of LOX [37].
Both treatments reduced rECT compaction (Fig. 6A, B) and stiﬀness
(Fig. 6C, D) with LatA showing the more pronounced eﬀect. Neither
LatA nor CCG-203971 aﬀected the rECT extensibility (Fig. 6E). Im-
portantly, LatA and CCG-203971 reduced the expression of LOX in rECT
signiﬁcantly after 5 days of treatment (Fig. 6F). This data supports the
hypothesis that ROCK regulates LOX expression via the actin/MRTF/
SRF pathway.
3.6. LOX inhibition resembles the eﬀect of ROCK inhibition on rECT
stiﬀness
As described above, inhibition of ROCK, of actin polymerization,
and of MRTF translocation consistently reduced LOX expression in
rECT. We therefore analysed the impact of LOX inhibition by BAPN on
Fig. 3. ROCK inhibition regulates LOX expression in rECT. rECT were generated with NRCF and collagen I and were cultured in the absence (Control) or presence of
10 μM Fasudil or 3 μM H1152P. A) After 5 days in culture, RNA was isolated from rECT and subjected to qPCR analysis. In total RNA from 3 to 8 independent samples
were analysed. All values are normalized to the mean of the housekeeping genes porphobilinogen deaminase and β-glucuronidase. Given are the means+SEM and
the diﬀerences were evaluated by 2-way-ANOVA, *p < .05 vs. Control. B-D) After 1 day (d1) and 5 days (d5) of treatment rECT were homogenized and protein levels
of LOX (B), ROCK1 (C) and ROCK2 (D) were detected by immunoblot analyses. Shown are representative immunoblots (upper panel) and the quantiﬁcation of 3
independent experiments in which at least 7 rECT were investigated. The data is given normalized by β-actin and relative to control at day 1 as mean+SEM.
Diﬀerences were evaluated by 1-way-ANOVA, *p < .05 vs. Control-d1.
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the morphology of rECT. BAPN alone had no eﬀect on tissue compac-
tion and did not alter the inhibitory eﬀect of H1152P on tissue com-
paction (Fig. 7A, B). By contrast, BAPN reduced tissue stiﬀness in a
similar way to H1152P. The combined application of both inhibitors
showed no additive eﬀect on tissue stiﬀness (Fig. 7C, D). Similar to
H1152P, BAPN did not impair cell viability, as determined from cells
isolated from rECT (Fig. 7E, F). Cell cycle analysis of the re-isolated
cells veriﬁed the increase in the percentage of G2M phase cells after
H1152P treatment (see Fig. 1J). This was not an indirect consequence
of the decrease in tissue stiﬀness, as BAPN treatment did not alter cell
cycle distribution (Fig. 7G). Moreover, BAPN alone did not alter the
transcription of SMA and LOX (Fig. 7H) supporting the role of ROCK in
their regulation. These ﬁndings indicate that the ROCK-dependent
regulation of LOX result in changes in tissue stiﬀness, but not in tissue
(caption on next page)
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compaction.
3.7. ROCK inhibition reduced compaction and stiﬀness of hECT
To ensure that the observed ROCK inhibitor-induced decrease in
rECT compaction and stiﬀness is not species-speciﬁc or dependent on
the maturation state of the cells, we generated hECT from normal adult
human ventricular cardiac ﬁbroblasts and bovine collagen I. The tissues
were treated with 10 μM Fasudil or 3 μM H1152P. Comparable to the
rat tissues, the ROCK inhibitor-treated hECT showed decreased com-
paction (Fig. 8A, B) as well as a strong reduction in tissue stiﬀness re-
presented by the signiﬁcantly lower Young's moduli (Fig. 8C, D). A
slight increase in the extensibility of H1152P-treated hECT was found
(Fig. 8E). In line with our ﬁndings for rECT, H1152P exhibited a
stronger eﬀect than Fasudil. ROCK inhibition by Fasudil or H1152P in
hECT also resulted in a reduction of LOX gene transcription and protein
expression (Fig. 8F, G).
3.8. ROCK inhibition reduces stiﬀness of rEHM
Finally, we wanted to know if the observed diﬀerences in control
and ROCK inhibitor-treated ECT translate into heterocellular rat en-
gineered heart muscle (rEHM). We therefore generated rEHM which
were cultured for the last 7 days in the presence of either 10 μM Fasudil
or 3 μM H1152P. Similar to the ECT experiments, both ROCK inhibitors
signiﬁcantly increased the cross-sectional areas of rEHM (Fig. 9A, B).
Next, we performed isometric force measurements and found that
ROCK inhibition reduced the resting tension of the rEHM reﬂecting a
decline in tissue stiﬀness (Fig. 9C). Interestingly, there was a trend
towards an increase in twitch tension of the rEHM (Fig. 9D). As the
degree of calcium sensitivity of rEHM is a measure of cardiomyocyte
maturation [38], we determined the EC50 values of the calcium-de-
pendent contractile response of the rEHM, but could not detect any
diﬀerence between the groups (Fig. 9E). As this argued for an im-
provement of the contractile function due to better tissue compliance,
we further subjected the rEHM to rheology. This conﬁrmed that the
stiﬀness of the Fasudil and H1152P-treated rEHM was reduced as
shown by representative stress-strain curves (Fig. 9F) and the lower
Young's moduli (Fig. 9G). Similar to rECT, no signiﬁcant change in
tissue extensibility was found (Fig. 9H).
4. Discussion
In diverse animal models it was demonstrated that ROCK1 or
ROCK2 deletion as well as their simultaneous inhibition result in a
suppression of ﬁbrotic processes in response to heart stress
[8,10,12,39–41]. The extensive intercellular communication in these
models makes it however impossible to discriminate between auto-,
para- and endocrine eﬀects, and thus to delineate the role of ROCKs in
diﬀerent cardiac cell types. Moreover, animal models are not suitable to
study the eﬀect of a certain protein on distinct cellular processes taking
place in cardiac ﬁbrosis including ﬁbroblast proliferation and contrac-
tion as well as ECM production, compression and remodelling. Mam-
malian models are also too elaborate to compare many diﬀerent con-
ditions or to perform extensive drug screening. These hurdles prompt
many researchers to study, solely or additionally, cardiac ﬁbroblast
behaviour in homogenous 2D cultures, which bear the disadvantage of
an unnatural stiﬀ substrate and the lack of an embedding matrix. The
consequence in 2D is a fast transition of isolated cardiac ﬁbroblasts into
myoﬁbroblasts, which are likely diﬀerent from their matrix-embedded
counterparts. We found in our study substantial diﬀerences between
cells in 2D culture and the embedded cells, which still represent myo-
ﬁbroblasts based on their expression of SMA. One intriguing example is
given by the cell cycle experiments. In 2D cultures around 60% of the
cells were found to be in G0G1 phase, in ECT around 90% of the cells
were in this phase indicating that the 3D environment reduces the
proliferation capacity of myoﬁbroblasts.
Taking these problems into consideration, we believe that tissue
engineering oﬀers several advantages in the research ﬁeld of cardiac
ﬁbrosis. Especially, the use of ECT is a straightforward approach. ECT
can be prepared in a very short time with cells from diﬀerent origins
and maturation states and in diﬀerent scales. Fibrotic stimuli like TGF-β
as well as anti-ﬁbrotic substances can be easily applied and in-
vestigated. The low number of necessary cells makes it possible to study
diﬀerent substances at the same time or in varying concentrations. This
allowed us to compare the eﬀects of Fasudil and H1152P, to demon-
strate the concentration-dependent eﬀect of SR-3677, to conﬁrm that
ROCKs play a role downstream of TGF-β in cardiac ﬁbroblasts beha-
viour as suggested before [10], and to validate the importance of ROCK-
dependent signalling events like the actin-MRTF-LOX regulation. In
addition to the presented pharmacological study we have demonstrated
in the past that ECT can be prepared from male and female cells to
study sex-diﬀerences in cardiac ﬁbrosis and from virally transduced
cells allowing loss- and gain-of function studies [15,18,30,42].
The ECT model is not only ﬂexible in its composition, but also in its
functional readout possibilities. Besides the analyses of gene expression,
cell viability and cell cycle, the most important readout is the de-
termination of the biomechanical properties. We performed ultimate
destructive tensile measurements in order to obtain information on the
tissue stiﬀness (Young's modulus) and on the strain to failure point
reﬂecting the maximal extensibility of a tissue. Both parameters are
independent of each other and are likely important for the considera-
tion whether or not a treatment or intervention is worth to follow-up in
more elaborate pre-clinical studies. This raises the question of how a
promising treatment should inﬂuence the biomechanics of ECT. It is
important to understand that our ECT model is a disease models as the
mean stiﬀness of the control tissues are around 10 times higher as the
reported values for healthy mammalian hearts [43,44]. One basic re-
quirement is therefore that an intervention reduces the stiﬀness of the
engineered tissue towards normal. In contrast, this intervention should
not negatively aﬀect the extensibility of the tissues as this gives reason
to suspect that it could result in the structural disintegration of the
Fig. 4. ROCK inhibition alters NRCF cell shape, cell cycle progression and LOX expression in 2D cultures. NRCF were treated with the indicated concentration of
H1152P and subjected to the respective analyses. A) The treated NRCF were ﬁxed after 48 h and stained with FITC-phalloidin (gray) and DAPI (blue). Images were
taken with a 20× objective and a ﬂuorescence microscope. Shown are representative merges of both channels. B) Based on the FITC-phalloidin images the areas of
attached cells were determined. Given are the means+SEM of 3 independent experiments. The diﬀerences were evaluated by 1way-ANOVA, *p < .05 vs. Control. C)
The treated NRCF were detached and the cell diameters were determined with the help of the Casy TT system. Given are the means+SEM of 3 independent
experiments. D) The pre-treated, detached NRCF were seeded in 12-well plates in the absence or presence of a collagen I coat. Images were taken every 20min and
the percentage of attached cells was determined. Given are the means± SEM of 3 independent experiments. E) The NRCF were seeded in cell culture plates, treated
with the indicated concentrations of H1152P and ﬁxed 24 h after seeding (Day 0) as well as 1, 2 and 6 days later. The nuclei were stained with DAPI and counted
automatically. Given are the means± SEM of 5–6 independent experiments. The diﬀerences were evaluated by 2way-ANOVA, *p < .05 vs. Control. F-G) The NRCF
were treated for 48 h, detached, ﬁxed, stained and subjected to FACS analysis. The numbers of bi-nucleated cells (F) and of cells in diﬀerent cell cycle phases (G) were
analysed. Given are the means+SEM of 4–6 independent experiments. The diﬀerences were evaluated by 1way- (F) or 2way ANOVA (G), *p < .05 vs. Control. H)
The NRCF were treated for 48 h as indicated and apoptotic cells were identiﬁed by a life cell annexin V/propidium iodide stain. The percentages of apoptotic cells are
given as means+SEM of 3 independent experiments. The diﬀerences were evaluated by 1way-ANOVA, *p < .05 vs. Control. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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myocardium in vivo.
We used in our study three diﬀerent ROCK inhibitors, which dis-
played all similar eﬀects on ECT properties, however, with diﬀerent
potencies. Among the isoquinoline inhibitors, H1152P reduced more
potently tissue compaction and stiﬀness than Fasudil, which is in line
with their reported Ki and IC50 values. In general, the published IC50
values of both inhibitors are substantially higher as their Ki value and
seem to vary dependent on the cell type and the investigated eﬀect.
Fig. 5. ROCK inhibition regulates LOX and SMA expression in 2D NRCF cultures. RNA and protein were extracted from NRCF treated for 48 h and 5 d with 300 nM or
3 μM H1152P and subjected to qPCR and immunoblot analyses. The following transcripts and proteins were analysed: LOX (A, G), SMA (B, H), ROCK1 (C, I), ROCK2
(D, J). SMA transcription was additionally analysed in rECT (C). A-E) All qPCR values were normalized to the mean of the housekeeping genes porphobilinogen
deaminase and hypoxanthine phosphoribosyltransferase 1 and are given relative to control. In total RNA from 4 independent experiments were analysed. Shown are
the means+SEM. The diﬀerences were evaluated by 1-way-ANOVA or an unpaired t-test (ECT), *p < .05. F) Representative immunoblots of LOX, SMA, ROCK1,
ROCK2 and of the housekeeping proteins α-tubulin, β-actin and GAPDH are shown. G-J) Protein levels were normalized by the housekeeping proteins and are given
relative to control 48 h as means+SEM of 4 independent experiments. The diﬀerences were evaluated by 1-way-ANOVA, *p < .05.
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Moreover, the relative diﬀerences between Ki and IC50 are not identical
as the Ki values diﬀer by 200-fold (Fasudil Ki 330 nM, H1152P Ki
1.6 nM) [32] and the IC50 by around 2 to 20-fold in comparative studies
(Fasudil IC50 range 2 μM–10 μM, H1152P IC50 range 200 nM-2 μM)
[45–48]. Based on these published values, we decided to use in our
study inhibitor concentrations which are close to the reported maximal
IC50 values in order to minimize oﬀ-target eﬀects, but which still allow
suﬃcient inhibition. Under these conditions both inhibitors fulﬁlled the
requirement of reducing the stiﬀness of rECT to values published for the
normal rat heart [43] and importantly without aﬀecting the tissue ex-
tensibility. In hECT, however, both inhibitors were not as eﬀective in
stiﬀness reduction and thus didn't meet the criteria. In comparison to
Fasudil and H1152P, the pyrazol-phenyl inhibitor SR-3677 was most
potent in reducing rECT compaction and stiﬀness. The IC50 for the
decline in the Young's modulus was around 10 nM, which is 3 times
above the reported IC50 for ROCK2 and 5 times below the IC50 of
ROCK1 [34], which might indicate that ROCK2 is more important for
tissue stiﬀening that ROCK1. Future studies are needed to validate the
isoform-speciﬁcity, the potential therapeutic value and the oﬀ-target
eﬀects of SR-3677. This is also true for the many new ROCK inhibitors,
which have been developed in the last few years, mainly driven by their
promising therapeutic eﬀect in the treatment of glaucoma [49]. In-
dependent of their chemistries, they all act as ATP competitors, and
thus oﬀ-target eﬀects are almost inevitable. In general, oﬀ-target eﬀects
are often responsible for adverse actions of a drug, but they can also
directly hamper the desired eﬀect. For example, Fasudil displays a
diﬀerence in its inhibitory potency between ROCK and PKA of only 10-
to 20-fold and thus partial PKA inhibition is likely when Fasudil is used
[50,51]. Combined inhibition of ROCK and PKA might be, however,
counter-productive in the context of cardiac ﬁbrosis. In line with this
Fig. 6. Inhibition of actin polymerization and MRTF translocation reduced rECT compaction and stiﬀness as well as LOX expression. rECT were generated with NRCF
and collagen I and were cultured for 5 days in the absence (Control) or presence of 7 ng/mL LatA or 50 μM CCG-203971. A) Representative images of rECT are shown.
B) The cross sectional areas (CSA) were determined by image analysis. Given are the means± SEM of 16 individual tissues from 3 independent experiments.
Diﬀerences were analysed by 1way-ANOVA, *p < .05 vs. Control. C) Representative stress-strain curves from destructive tensile measurements are shown. D-E) The
Young's moduli (D) and the strain to failure point (E) were extracted from the obtained stress-strain curves. Given are the means+SEM of 16 individual tissues from 3
independent experiments. Diﬀerences were analysed by 1way-ANOVA, *p < .05 vs. Control. F) Proteins were extracted from rECT treated for 1 or 5 days and
subjected to immunoblot analysis. Shown are representative immunoblots of LOX and β-actin (left). LOX expression was normalized to β-actin expression and is given
relative to Control-d1. The values are means+SEM of 4 independent experiments (right). Diﬀerences were analysed by 1way-ANOVA, *p < .05.
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Fig. 7. LOX inhibition resembles the eﬀect of ROCK inhibition on rECT. rECT were generated with NRCF and collagen I and were cultured for 5 days in the absence
(Control) or presence of 3 μM H1152P and/or 100 μM BAPN. A) Representative images of rECT are shown. B) The cross sectional areas (CSA) were determined by
image analysis. Given are the means+SEM of 12 individual tissues from 4 independent experiments. Diﬀerences were analysed by 1way-ANOVA, *p < .05 vs.
Control. C) Representative stress-strain curves from destructive tensile measurements are shown. D) The Young's moduli were calculated based on the obtained stress-
strain curves. Given are the means+SEM of 12 individual tissues from 4 independent experiments. Diﬀerences were analysed by 1way-ANOVA, *p < .05 vs. Control.
E-F) The NRCF were re-isolated from rECT and the cell number (E) and viability were measured with the Casy TT system. Given are the means+SEM of 3
independent experiments. G) Cell cycle distribution was analysed by FACS in re-isolated, ﬁxed and stained cells. Given are the percentages of cells at G0/G1, S and
G2/M stages as means+SEMs of 4 independent experiments measured each in 3 technical replicates, *p < .05 vs. Control as assessed by 2way ANOVA. H) RNA was
isolated from rECT and subjected to qPCR analysis. In total RNA from 12 rECT was analysed. All values are normalized to the mean of the housekeeping genes
porphobilinogen deaminase and hypoxanthine phosphoribosyltransferase 1. Shown are the means+SEM and the diﬀerences were evaluated by 1-way-ANOVA,
*p < .05 vs. Control, #p < .05 vs. BAPN.
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hypothesis it was shown by up-stream activation of PKA and its direct
inhibition, that PKA possesses certain anti-ﬁbrotic properties in rat
cardiac ﬁbroblasts [52]. Moreover, we demonstrated earlier that the
augmented degradation of cAMP by overexpression of phosphodies-
terase 2 (PDE2) resulted in an enhanced cardiac ﬁbroblast to myoﬁ-
broblast conversion and an increased stiﬀness of rECT [42]. We
therefore believe that identifying a highly speciﬁc ROCK inhibitor is
crucial for taking ROCK inhibition forward into clinical studies on ﬁ-
brosis in the future.
It is, however, clear that drug testing in a homogeneous cardiac
ﬁbroblast models is not suﬃcient to estimate its therapeutic potential.
Besides the above mentioned criteria on tissue stiﬀness and ex-
tensibility, a further requirement is that a drug does not interfere with
the contractile behaviour of cardiomyocytes. The EHM model oﬀers
here a similar fast and simple approach to test for this requirement. By
using this model, we could show that ROCK inhibition induced similar
eﬀects on rEHM stiﬀness and compaction as found for rECT, implying
that cardiac ﬁbroblasts are the main target aﬀecting both processes.
Importantly, ROCK inhibition did not negatively interfere with the
contractile function of the EHM, but showed by trend a slight im-
provement. Due to the unchanged calcium sensitivity, we believe that
this improvement is more likely based on a better diastolic compliance
of the tissues than on molecular changes in the excitation-contraction
coupling in cardiomyocytes, which was described to be a potential
consequence of ROCK inhibition [53,54]. Similar as found in ECT,
ROCK inhibition did not aﬀect tissue extensibility. This could explain
why despite its anti-ﬁbrotic eﬀect ROCK inhibition was not associated
with an increase in ventricular rupture after myocardial infarction in
animals [55–57]. Taken together our data fuel the idea that the in-
hibition of ROCK could be an eﬀective therapeutic option for diastolic
Fig. 8. ROCK inhibition reduced compaction and stiﬀness of hECT. hECT were prepared from normal adult human ventricular cardiac ﬁbroblasts and collagen I. The
hECT were cultured for 5 days in the absence (Control) or presence of 10 μM Fasudil or 3 μM H1152P. A) Representative images of hECT are given. B) The cross
sectional areas (CSA) were determined by image analysis. Given are the means+SEM of 18 to 20 individual tissues from at least 3 independent experiments.
Diﬀerences were analysed by 1way-ANOVA, *p < .05 vs. Control. C) Representative stress-strain curves from destructive tensile measurements are shown. D) The
Young's moduli were calculated based on the obtained stress-strain curves. Given are the means+SEM of 16–20 hECT from 5 independent experiments. Diﬀerences
were evaluated by 1way-ANOVA, *p < .05 vs. Control. E) The strain to failure point was extracted from the obtained rheology data. Given are the means± SEM of
16–20 hECT from 5 independent experiments. F) RNA from 3 independent experiments was analysed. All values are normalized to the mean of the housekeeping
genes porphobilinogen deaminase and hypoxanthine phosphoribosyltransferase 1. Shown are the means+SEM and the diﬀerences were evaluated by 1way-ANOVA,
*p < .05 vs. Control.
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dysfunction of the heart. This is supported by animal studies and pre-
liminary clinical trials. For example, in a pressure overload rat model
the ROCK inhibitor GSK-57637 signiﬁcantly attenuated diastolic dys-
function. Interestingly, the ACE inhibitor Ramipril was not as eﬀective
as GSK-57637 [58]. Moreover, deletion of ROCK2 from cardiac
myoﬁbroblasts in mice reduced the diastolic dysfunction after chronic
Ang II treatment [10]. Finally, in two clinical studies Fasudil was shown
to improve diastolic dysfunction in patients with Diabetes type 2 and in
patients with reactive pulmonary hypertension both associated with left
ventricular impairment, but with preserved ejection fraction [59,60].
Fig. 9. ROCK inhibition reduced tissue stiﬀness of rEHM. rEHM were prepared from total neonatal cardiac cells and cultured for 7 days until they were fully
consolidated and then transferred onto phasic stretchers for mechanical load for further 7 days. During this phase, the rEHM were treated with 10 μM Fasudil or 3 μM
H1152P. A) Shown are representative images of control-, Fasudil-, and H1152P-treated rEHM. B) Diﬀerences in calculated cross sectional areas (CSA) of the rEHM are
shown as means+SEM of 23 to 28 rEHM resulting from 5 independent cell isolations. C-D) Isometric force measurements were performed in an organ bath in the
presence of increasing concentrations of calcium. C) The resting forces and D) contraction forces normalized by the CSA are given as means± SEM of 29–31 rEHM
from 5 independent experiments. Diﬀerences were evaluated by 2way-ANOVA, *p < .05 vs. Control. E) The EC50 values for the calcium sensitivity of the contractile
function were calculated based on the measured contraction forces/CSA. F) The rEHM were further subjected to destructive tensile measurements. Representative
stress-strain curves are depicted. G) The Young's moduli were calculated based on the obtained stress-strain curves. Given are the means+SEM of 13–20 rEHM from
at least 3 independent experiments. The diﬀerences were evaluated by 1-way-ANOVA, *p < .05 vs. Control. H) The strain to failure point was calculated based on
the obtained rheology data. Given are the means+SEM of 13–20 rEHM from 3 independent experiments.
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Our work highlights not only ROCK inhibition as an interesting
therapeutic option but also contributes to the understanding of the
underlying mechanisms. In former studies the anti-ﬁbrotic eﬀect of
ROCK inhibitors or ROCK deletion has been attributed to their ability to
reduce the expression of ﬁbrosis-associated genes [61]. Our results
show that ROCK inhibition has little eﬀect on the transcription of pro-
ﬁbrotic genes and regulators of the cardiac ﬁbroblast ECM when em-
bedded in a 3D matrix. We found no change in Col1a1, Col3a1, Bi-
glycan, Decorin, LGALS3, CTGF, and TGF-β transcription, an up- and
down-regulation regulation of MMP2 and MMP12 by H1152P only, and
a down-regulation of HAS2 and LOX by both inhibitors. We could
conﬁrm by 2D cultures that LOX expression is reduced after 48 h on
RNA and protein level as well as on protein level in the ECT after 1 day
treatment. The changes in LOX protein levels after 5 days were not as
pronounced as after shorter incubation periods. Similar reductions in
LOX gene transcription as a consequence of ROCK inhibition has been
reported before. It was shown that Y27632 reduced LOX RNA in
NIH3T3 ﬁbroblasts [62], Fasudil in astrocytes [63], and SLx-2119 in
human pulmonary artery smooth muscle cells as well as human dermal
ﬁbroblasts [64]. This led us to the hypothesis that LOX is not only
regulated by Hif1α [65,66], peroxisome proliferator-activated receptor
γ [67], SMAD 2/3 and AP1 [68], as well as by the nuclear factor I [69],
but also by the RhoA/ROCK-regulated, actin-dependent MRTF/SRF
transcriptional complex [70,71]. In line with this hypothesis, it has
been demonstrated by ChIP- and RNA-sequencing that the MRTF/SRF
transcriptional complex binds in a serum-dependent manner in proxi-
mity to the LOX gene and that serum induces LOX transcription de-
pendent on actin [36]. As the functionality of this pathway has never
been tested before, we treated our rECT with the actin polymerization
inhibitor LatA or the MRTF translocation inhibitor CCG-20397. Both
substances interfered with tissue compaction and stiﬀness and most
importantly they reduced the expression of LOX. We therefore tested
next the eﬀect of the inhibition of LOX and likely of LOX homologs
(LOX-like 1-4) by the pan-inhibitor BAPN [72,73] and found that it
mimicked the phenotype of ROCK inhibition with respect to ECT stiﬀ-
ness. This anti-ﬁbrotic eﬀect of BAPN is in line with data from several in
vivo studies. For example, BAPN treatment was found to reduce left
ventricular stiﬀness and collagen content in a volume overload rat
model [74,75], to diminish the extent of cardiac ﬁbrosis in rats sub-
jected to a high fat diet [76], and to attenuated cardiac ﬁbrosis and
ventricular dilatation in a murine myocardial infarction model [77].
In summary, we have shown that our two-tiered engineered tissue
approach oﬀers several advantages in drug testing and signal pathway
delineation in the setting of cardiac ﬁbrosis. We found that ROCK in-
hibition, partly via reducing LOX expression, oﬀers an interesting
therapeutic approach for cardiac ﬁbrosis.
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